Cover Image
市場調查報告書

Foamix Pharmaceuticals Ltd.:產品平台分析

Foamix Pharmaceuticals Ltd. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 341863
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
Foamix Pharmaceuticals Ltd.:產品平台分析 Foamix Pharmaceuticals Ltd. - Product Pipeline Review - 2016
出版日期: 2016年09月30日 內容資訊: 英文 42 Pages
簡介

Foamix Pharmaceuticals Ltd. (原Foamix Ltd.)是專注於臨床實驗階段的製藥公司,正在開發及商品化皮膚科用局部製劑產品。該公司產品主要有痤瘡(粉刺),膿痂疹,酒糟,化療誘發性皮疹等的治療藥。 其他也提供一般皮膚症狀用開發平台臨床實驗初期階段的各種穩定泡沫製劑。

本報告提供Foamix Pharmaceuticals Ltd.的治療藥開發平台的現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥被評估及休止的計劃相關資訊等

Foamix Pharmaceuticals Ltd.的基本資料

  • Foamix Pharmaceuticals Ltd.概要
  • 主要資訊
  • 企業資料

Foamix Pharmaceuticals Ltd.:R&D概要

  • 主要的治療範圍

Foamix Pharmaceuticals Ltd.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Foamix Pharmaceuticals Ltd.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第Ⅱ期的產品/聯合治療模式
    • 第Ⅰ期的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Foamix Pharmaceuticals Ltd.:藥物簡介

  • doxycycline
  • FMX-103
  • minocycline
  • mometasone furoate
  • acyclovir
  • benzoyl peroxide
  • ciclopirox olamine
  • estradiol hemihydrate
  • imiquimod

Foamix Pharmaceuticals Ltd.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Foamix Pharmaceuticals Ltd.:最近的開發平台趨勢

Foamix Pharmaceuticals Ltd.:暫停中的計劃

Foamix Pharmaceuticals Ltd.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08140CDB

Summary

Global Markets Direct's, 'Foamix Pharmaceuticals Ltd. - Product Pipeline Review - 2016', provides an overview of the Foamix Pharmaceuticals Ltd.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by Foamix Pharmaceuticals Ltd., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of Foamix Pharmaceuticals Ltd.
  • The report provides overview of Foamix Pharmaceuticals Ltd. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses Foamix Pharmaceuticals Ltd.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features Foamix Pharmaceuticals Ltd.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate Foamix Pharmaceuticals Ltd.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Foamix Pharmaceuticals Ltd.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Foamix Pharmaceuticals Ltd.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Foamix Pharmaceuticals Ltd. Snapshot
    • Foamix Pharmaceuticals Ltd. Overview
    • Key Facts
  • Foamix Pharmaceuticals Ltd. - Research and Development Overview
    • Key Therapeutic Areas
  • Foamix Pharmaceuticals Ltd. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Foamix Pharmaceuticals Ltd. - Pipeline Products Glance
    • Foamix Pharmaceuticals Ltd. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Foamix Pharmaceuticals Ltd. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Foamix Pharmaceuticals Ltd. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Foamix Pharmaceuticals Ltd. - Drug Profiles
    • (urea + lactic acid) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • acyclovir - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benzoyl peroxide - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • betamethasone valerate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ciclopirox olamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • doxycycline - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • estradiol hemihydrate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FMX-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FMX-102 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FMX-103 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • imiquimod - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mometasone furoate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • urea - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Foamix Pharmaceuticals Ltd. - Pipeline Analysis
    • Foamix Pharmaceuticals Ltd. - Pipeline Products by Target
    • Foamix Pharmaceuticals Ltd. - Pipeline Products by Route of Administration
    • Foamix Pharmaceuticals Ltd. - Pipeline Products by Molecule Type
    • Foamix Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action
  • Foamix Pharmaceuticals Ltd. - Dormant Projects
  • Foamix Pharmaceuticals Ltd. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Foamix Pharmaceuticals Ltd., Key Facts
  • Foamix Pharmaceuticals Ltd. - Pipeline by Indication, 2016
  • Foamix Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016
  • Foamix Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016
  • Foamix Pharmaceuticals Ltd. - Combination Treatment Modalities in Pipeline, 2016
  • Foamix Pharmaceuticals Ltd. - Partnered Products in Pipeline, 2016
  • Foamix Pharmaceuticals Ltd. - Partnered Products/ Combination Treatment Modalities, 2016
  • Foamix Pharmaceuticals Ltd. - Phase III, 2016
  • Foamix Pharmaceuticals Ltd. - Phase II, 2016
  • Foamix Pharmaceuticals Ltd. - Phase I, 2016
  • Foamix Pharmaceuticals Ltd. - Preclinical, 2016
  • Foamix Pharmaceuticals Ltd. - Pipeline by Target, 2016
  • Foamix Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2016
  • Foamix Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016
  • Foamix Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2016
  • Foamix Pharmaceuticals Ltd. - Dormant Developmental Projects,2016
  • Foamix Pharmaceuticals Ltd., Subsidiaries

List of Figures

  • Foamix Pharmaceuticals Ltd. - Pipeline by Top 10 Indication, 2016
  • Foamix Pharmaceuticals Ltd. - Pipeline by Stage of Development, 2016
  • Foamix Pharmaceuticals Ltd. - Monotherapy Products in Pipeline, 2016
  • Foamix Pharmaceuticals Ltd. - Pipeline by Target, 2016
  • Foamix Pharmaceuticals Ltd. - Pipeline by Route of Administration, 2016
  • Foamix Pharmaceuticals Ltd. - Pipeline by Molecule Type, 2016
  • Foamix Pharmaceuticals Ltd. - Pipeline Products by Mechanism of Action, 2016
Back to Top